Physician profile
Sandra Lee Rebish
NPI 1235252289
$746,363.73
in general payments reported to CMS, 2019-2025
15 companies · $112K in 2025
The $112K reported for 2025 was more than what 98% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $497 · 2020: $2,151 · 2021: $154 · 2022: $159 · 2023: $67K · 2024: $565K · 2025: $112K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $637K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $64K · Travel and Lodging: $40K · Food and Beverage: $2,120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $637,200.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $64,000.00 |
| Travel and Lodging | $40,082.06 |
| Food and Beverage | $2,119.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $430,182.02 | 2023-2025 | Opzelura |
| Ucb, INC. | $240,589.54 | 2024 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $67,079.12 | 2023-2024 | Winlevi |
| Janssen Scientific Affairs, LLC | $4,250.00 | 2024 | Tremfya |
| Allergan, INC. | $2,098.54 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $596.66 | 2019-2024 | |
| Galderma Laboratories, L.P. | $461.07 | 2021-2025 | |
| Janssen Biotech, INC. | $257.28 | 2021-2024 | Tremfya |
| Abbvie INC. | $234.89 | 2019-2024 | |
| Merz North America, INC. | $228.26 | 2022-2023 | |
| Genzyme Corporation | $163.68 | 2024-2025 | |
| Abbott Laboratories | $151.87 | 2024-2025 | Freestyle Libre 3 |
| Amgen INC. | $34.51 | 2025 | Otezla |
| Sensus Healthcare, INC. | $20.57 | 2019 | |
| Dusa Pharmaceuticals, INC. | $15.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Rebish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.